Literature DB >> 34151202

Identification of Novel MicroRNAs Targeting SARS-CoV-2 through the Regulation of TMPRSS2/PI3K/AKT/PTEN Alignment in Lung Cancer: An in Silico Analysis.

Debasmita Mukhopadhyay1, Nour AlSawaftah1, Ghaleb A Husseini1.   

Abstract

In this study, we investigated the interactions between SARS-CoV-2 and miRNAs associated with lung cancer using bioinformatic approaches. A special focus was placed on TMPRSS2 and lung cancer progression pathways involving AKT/PI3K/PTEN genes.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID： 34151202      PMCID： PMC8204320          DOI： 10.1021/acsptsci.1c00040

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN： 2575-9108


  17 in total

Review 1.  Emerging aspects of microRNA interaction with TMPRSS2-ERG and endocrine therapy.

Authors:  Eugenio Zoni; Sofia Karkampouna; George N Thalmann; Marianna Kruithof-de Julio; Martin Spahn
Journal:  Mol Cell Endocrinol       Date:  2017-02-09       Impact factor: 4.102

2.  miR-221 Is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer.

Authors:  Aida Gordanpour; Aleksandra Stanimirovic; Robert K Nam; Carlos S Moreno; Christopher Sherman; Linda Sugar; Arun Seth
Journal:  Anticancer Res       Date:  2011-02       Impact factor: 2.480

3.  Pathogenesis of lung cancer signalling pathways: roadmap for therapies.

Authors:  E Brambilla; A Gazdar
Journal:  Eur Respir J       Date:  2009-06       Impact factor: 16.671

4.  High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma.

Authors:  Valsamo K Anagnostou; Gerold Bepler; Konstantinos N Syrigos; Lynn Tanoue; Scott Gettinger; Robert J Homer; Daniel Boffa; Frank Detterbeck; David L Rimm
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

Review 5.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.

Authors:  C Mascaux; N Iannino; B Martin; M Paesmans; T Berghmans; M Dusart; A Haller; P Lothaire; A-P Meert; S Noel; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

Review 6.  PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around.

Authors:  Anastasios Gkountakos; Giulia Sartori; Italia Falcone; Geny Piro; Ludovica Ciuffreda; Carmine Carbone; Giampaolo Tortora; Aldo Scarpa; Emilio Bria; Michele Milella; Rafael Rosell; Vincenzo Corbo; Sara Pilotto
Journal:  Cancers (Basel)       Date:  2019-08-09       Impact factor: 6.639

Review 7.  Role of Host and Pathogen-Derived MicroRNAs in Immune Regulation During Infectious and Inflammatory Diseases.

Authors:  Kumari Chandan; Meenakshi Gupta; Maryam Sarwat
Journal:  Front Immunol       Date:  2020-01-24       Impact factor: 7.561

8.  The Biological Role of PI3K Pathway in Lung Cancer.

Authors:  Evangelos G Sarris; Muhammad W Saif; Kostas N Syrigos
Journal:  Pharmaceuticals (Basel)       Date:  2012-11-20

9.  Targeting TMPRSS2 in SARS-CoV-2 Infection.

Authors:  Linda B Baughn; Neeraj Sharma; Eran Elhaik; Aleksandar Sekulic; Alan H Bryce; Rafael Fonseca
Journal:  Mayo Clin Proc       Date:  2020-07-19       Impact factor: 7.616

10.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582
View more
  1 in total

Review 1.  Live and let die: signaling AKTivation and UPRegulation dynamics in SARS-CoVs infection and cancer.

Authors:  Mariana Suaya; Gonzalo Manuel Sánchez; Antonella Vila; Analía Amante; Mercedes García Carrillo; María Cotarelo; Matías Blaustein
Journal:  Cell Death Dis       Date:  2022-10-03       Impact factor: 9.685
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.